Seattle Genetics

(NASDAQ: SGEN)
Healthcare  |  Biotechnology
83.38 0.96 1.16%
Stock Price | Oct. 15, 2019, 4 p.m.
0 Followers
Bid: 0.0
Ask: 0.0
Prev. Close: 82.42
52 Week Low: 50.71
52 Week High: 88.2
PE Ratio: 0.0
Dividend Yield: 0.0%

Company Summary

Seattle Genetics is a biotech firm focused on the development of monoclonal antibody-based therapies. The company's lead product, Adcetris, has received approval for advanced frontline, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other early-stage programs in trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Read more Read less

Recently Viewed Tickers

Free Stock Watchlist 09/07/2016

3 years ago